A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2005
This study will evaluate the efficacy, safety, tolerability, and pharmacokinetics of GK Activator (2) in combination with metformin, compared to that of placebo (metformin monotherapy), in patients with type 2 diabetes mellitus. Patients will continue on their stable dose of metformin and will be randomized to receive either GK Activator (2) or placebo. The anticipated time on study treatment is less than 3 months, and the target sample size is 100-500 individuals.
Epistemonikos ID: 2f12e5e4ecdbbf1dc0e2655df5fe9ea7cb1462a3
First added on: May 04, 2024